Clinical Trial Outcomes Risk: Apogee's product candidates are in early-stage clinical development, and there is no guarantee that they will demonstrate the necessary safety and efficacy to advance through clinical trials or gain regulatory approval. Failure in any clinical trial stage would significantly harm the company's prospects.

Regulatory Approval Process Risk: Even with positive clinical data, Apogee may not receive necessary regulatory approvals from agencies such as the FDA or EMA. The regulatory pathway is complex, lengthy, and subject to evolving requirements, which could lead to delays or outright rejection of their product candidates.

Intense Competition Risk: The therapeutic areas targeted by Apogee, particularly immunology and inflammation, are highly competitive. Established pharmaceutical companies and other biotechnology firms may develop more effective or safer products, or advance their candidates more quickly, potentially rendering Apogee's candidates uncompetitive.